Neuroendocrine Tumor

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

FDA approval · 2018-08-09
FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for NETSPOT (68Ga-DOTATATE) from Advanced Accelerator Applications USA, Inc., to modify and/or e…
FDA approval · 2018-03-09
FDA Approved: OCTREOTIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for octreotide acetate from Fresenius Kabi USA, LLC.
FDA approval · 2016-10-31
FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for NETSPOT (68GA-DOTATATE) submitted by Advanced Accelerator Applications USA, Inc., expanding …
FDA approval · 2016-06-01
FDA Approved: NETSPOT — Original Application (Advanced Accelerator Applications USA, Inc)
FDA approved NETSPOT (68Ga-DOTATATE) from Advanced Accelerator Applications USA, Inc for use as a diagnostic PET radiopharmaceutical. It is …
FDA approval · 2016-05-20
FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) by Novartis, resulting in changes to the product …
Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
FDA approval · 2015-11-02
FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) submitted by Ipsen Biopharmaceuticals, Inc.
FDA approval · 2015-06-01
FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) filed by Ipsen Biopharmaceuticals, Inc., updating the …
FDA approval · 2013-05-23
FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Octreotide acetate submitted by Mylan Institutional LLC.